e-Article
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Document Type
Article
Author
Javle, Milind ; Roychowdhury, Sameek; Kelley, Robin Kate; Sadeghi, Saeed; Macarulla, Teresa; Weiss, Karl Heinz; Waldschmidt, Dirk-Thomas; Goyal, Lipika; Borbath, Ivan; El-Khoueiry, Anthony; Borad, Mitesh J; Yong, Wei Peng; Philip, Philip A; Bitzer, Michael; Tanasanvimon, Surbpong; Li, Ai; Pande, Amit; Soifer, Harris S; Shepherd, Stacie Peacock; Moran, Susan; Zhu, Andrew X; Bekaii-Saab, Tanios S; Abou-Alfa, Ghassan K
Source
In The Lancet Gastroenterology & Hepatology October 2021 6(10):803-815
Subject
Language
ISSN
2468-1253